Lowey Dannenberg, on behalf of named plaintiff Premera Blue Cross, is leading a class on behalf of Third-Party Payers of Amitiza (Lubiprostone) against Takeda Pharmaceutical Company Ltd. and related entities. Plaintiff allege that drug manufacturers Takeda and Sucampo, acting as partners, reached an anticompetitive agreement with generic manufacturer Par Pharmaceutical, Inc. in 2014, under which Par would delay market entry of its generic Amitiza until January 1, 2021, at which point it could either sell its own generic product or a Sucampo-supplied product, and the parties would agree to split the generic revenue 50/50. 

On May 18, 2026 after a five week trial, a nine member federal court jury in Boston, Massachusetts awarded a verdict of $63.2 million in damages to the certified class of end-payor purchasers.